Trails Edge Capital Partners LP Makes New $8.45 Billion Investment in CAMP4 Therapeutics Corporation $CAMP

Trails Edge Capital Partners LP acquired a new position in shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 1,932,937 shares of the Wireless communications provider’s stock, valued at approximately $8,446,935,000. CAMP4 Therapeutics comprises about 1.3% of Trails Edge Capital Partners LP’s holdings, making the stock its 27th biggest holding.

Several other large investors have also modified their holdings of CAMP. Jefferies Financial Group Inc. acquired a new stake in CAMP4 Therapeutics during the 4th quarter worth $70,000. Bank of America Corp DE purchased a new stake in CAMP4 Therapeutics in the fourth quarter valued at $86,000. OMERS ADMINISTRATION Corp acquired a new position in CAMP4 Therapeutics in the fourth quarter valued at $115,000. Goldman Sachs Group Inc. acquired a new position in CAMP4 Therapeutics in the fourth quarter valued at $115,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of CAMP4 Therapeutics during the second quarter worth about $36,000.

CAMP4 Therapeutics Stock Performance

NASDAQ CAMP opened at $4.45 on Wednesday. The firm’s fifty day moving average is $4.13 and its two-hundred day moving average is $4.35. CAMP4 Therapeutics Corporation has a one year low of $1.41 and a one year high of $7.75. The firm has a market cap of $279.24 million, a PE ratio of -1.92 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The business had revenue of $1.78 million for the quarter. Research analysts predict that CAMP4 Therapeutics Corporation will post -0.57 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on CAMP. Weiss Ratings upgraded CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, June 10th. UBS Group set a $15.00 price objective on CAMP4 Therapeutics in a research note on Friday, August 14th. Finally, Piper Sandler reissued an “overweight” rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.56.

Insider Activity at CAMP4 Therapeutics

In related news, Director Richard A. Young acquired 16,378 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was bought at an average cost of $1.65 per share, with a total value of $27,023.70. Following the transaction, the director owned 186,388 shares of the company’s stock, valued at $307,540.20. The trade was a 9.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Andrew J. Schwab sold 32,018 shares of CAMP4 Therapeutics stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $4.50, for a total value of $144,081.00. Following the completion of the transaction, the director owned 2,433,280 shares in the company, valued at $10,949,760. This trade represents a 1.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have acquired 36,031 shares of company stock valued at $59,451 and have sold 193,603 shares valued at $887,992. 21.69% of the stock is owned by corporate insiders.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.